EXECUTIVE ENGAGEMENTS
OUTREACH
11708
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
3981
Interactions with Platform & by Email
PARTICIPANTS
955
Unique # Participated
VALIDATIONS
96
Responses Validated*
COMPETITORS
335
Responses Validated*
* Login for a full stack data experience
DATE
MAY 2021
TABLES
47
PAGES
817
EDITION
1
PRICE
USD 5800
*Engagement stats are ongoing and dynamic
HIGHLIGHTS
Global COVID-19 Vaccines Market to Reach 9.7 Billion Doses by 2025
Global COVID-19 annual vaccine doses estimated at 11 million doses in 2020 will reach 9.7 billion doses by 2027, displaying at a CAGR of 4.8% over the analysis period 2020-2025. In terms of value, the global market is projected to reach US$132.3 billion by the year 2025 up from the US$267 million estimated in the year 2020. Vaccine doses for children under 18 years, also analyzed as part of the report, will record a projected 90.5% CAGR over the analysis period.
Annual Doses in the U.S. to Plateau at 491 Million by 2025, While Africa Will Peak at 1.1 Billion Doses
Annual vaccine doses administered in the U.S. will plateau at 491 million doses by 2025 after peaking at 543 million doses in the year 2023. The country will record 2.1% CAGR for the period 2020 through 2025. China and Rest of Latin America will recorded the highest growth of 8.1% and 8.7% respectively over the said analysis period. Africa will remain the last region to catch up with the vaccine race. With just 823 million annual doses in 2021, the region is projected to record over 1.1 billion annual doses by the year 2025. In terms of value, annual vaccine doses in the U.S. is estimated at US$16 billion in year 2021, while Africa at the other end of scale weighs in at just US$5 billion for the same year. India, the new epicenter of the global pandemic will record the highest annual vaccine doses of 2.2 billion only in the year 2023.
Vaccines Doses for Under 18 Years to Record 90.5% CAGR
Global annual vaccines doses for children under 18 years estimated at 296.6 million doses in the year 2021, will reach a projected 3.5 billion doses by the year 2025, trailing a 90.5% CAGR. Regions with a large base of young population will witness the fastest growth. Middle East, Africa and Asia are all forecast to grow at 120.5%, 145.1% and 96.7% CAGR respectively. In China and India annual doses administered in this demographic cluster will increase from 109 million doses in 2021 to peak at 1.3 billion doses by the year 2025.
SELECT PLAYERS
Moderna, Inc.; Pfizer Inc./BioNTech; AstraZeneca/University of Oxford; Johnson & Johnson; CanSino Biologics, Inc.; China National Pharmaceutical Group Co., Ltd. (Sinopharm); Sinovac Biotech Ltd.; Novavax, Inc.; Inovio Pharmaceuticals; Sanofi/GlaxoSmithKline; Gamaleya Institute
SEGMENTS
» Age Group (18 Years & Above, Under 18 Years)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where Is The World Economy Headed in 2021? |
| EXHIBIT 1: COVID-19 Cases Worldwide by Country: As on May 01, 2021 |
| EXHIBIT 2: COVID-19 Cases in the US by State: As on May 01, 2021 |
| Increased Hospital Admissions and Deaths Characterize Second and Third Wave |
| EXHIBIT 14: Daily New Confirmed Cases (Per Million) by Select Country |
| So How Fast Or Slow Are We Moving? |
| EXHIBIT 3: How Fast the World is Vaccinated Will Determine How Soon the Pandemic Will End: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets |
| COVID-19 Vaccine Market Analysis in Million Doses by Region: 2020-2025 |
| EXHIBIT 4: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025 |
| COVID-19 Vaccine Market Breakdown in Million Doses by Region: 2021 & 2025 |
| EXHIBIT 5: Global Number of Annual COVID-19 Vaccine Doses (In US$ Million) for Years 2020 through 2025 by Geographic Region/Country - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets |
| COVID-19 Vaccine Market Analysis in US$ Million by Region: 2020-2025 |
| EXHIBIT 6: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025 |
| COVID-19 Vaccine Market Breakdown of Dollar Sales by Region: 2021 & 2025 |
| Progress on Vaccinations, Why Should Businesses Care? |
| These are Times When Questions Abound & Answers Are Few |
| With IMF’s Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish about a Global Economic Comeback. |
| EXHIBIT 7: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 |
| COVID-19 Infection Leaves Survivors Struggle with Psychological Complications |
| SECOND AND THIRD COVID-19 WAVES ENGULF VARIOUS REGIONS |
| Regional Spike in New Cases in US: Is a Fourth Wave of COVID-19 in Near Future |
| EUROPE |
| European Nations Ramp up Restrictions as Third Wave of COVID-19 Envelops Continent |
| Germany Prolongs Lockdown until June, 2021 |
| France: Night Curfew & Regionalized ‘Lockdown Lite’ |
| Greece Lifts Certain Restrictions |
| Sweden Vows People to Follow Guidelines |
| Norway: New Restrictions for Easter |
| Switzerland Prolongs Lockdown Measures |
| Spain Eases Restrictions |
| ASIA-PACIFIC |
| Fresh Wave of COVID-19 Spiraling Out of Control in Asia-Pacific |
| SOUTH AFRICAN, INDIAN, AND OTHER COVID-19 VIRUS VARIANTS |
| COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation’ to Pose Vaccine Challenge |
| Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse |
| Is South African Variant a Formidable Threat? |
| E484K Mutation Challenges Vaccine Developers |
| Rising Cases in South Africa & Other Countries |
| California Strain Emerges to be More Contagious and Deadly |
| Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines? |
| Mutated COVID-19 Variant Makes Oxford-AstraZeneca Vaccine Rollout to Go Haywire in South Africa |
| Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant |
| Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection |
| Moderna’s Variant-Specific Vaccine Candidate Ready for Clinical Study |
| AstraZeneca Plans to Adapt Covid-19 Vaccine against New Emerging Variants |
| New Research on Antibodies Efficacy against Variants |
| AN OVERVIEW OF COVID-19 VACCINE ROLLOUT |
| COVID-19 Vaccine Approval Details |
| EXHIBIT 9: Production Capacity by Company for Frontrunners in Millions of Doses for 2021 |
| COVID-19 Vaccine Funding Details |
| Pfizer/BioNTech’s COVID-19 Vaccine Receives World’s First Authorization |
| UK Clinches the First Position in the World to Approve Pfizer’s Vaccine |
| After UK, Pfizer’s Vaccine Gains Approval from the US and EU |
| BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU |
| Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production |
| After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA |
| Moderna Kick-Starts Inoculation in the US |
| AstraZeneca’s Vaccine - Third Globally to Obtain Approval |
| US FDA Clears J&J’s Single Shot Vaccine for Emergency Use |
| Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine |
| A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine |
| Johnson & Johnson's Adenovirus-based COVID-19 Vaccine: Better than Moderna or Pfizer? |
| Limitations |
| Russia Commences Mass Vaccination from Mid-December, 2020 |
| Russia’s Sputnik V Receives Approval for People Aged over 60 |
| Chinese Vaccine Development Scenario |
| China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm |
| Brazilian Authorities Approve Sinovac’s CoronaVac |
| AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India |
| Sanofi Starts Trials of Second Vaccine after Disappointing Results of the First Vaccine |
| 2. A REVIEW OF VARIOUS VACCINES UNDER CLINICAL TRIALS |
| EXHIBIT: COVID-19 VACCINES UNDER DEVELOPMENT |
| EXHIBIT 11: COVID-19 Vaccine Candidates in Human Clinical Trials |
| EXHIBIT 12: Vaccines in Pipeline by Technology |
| EXHIBIT 13: Vaccine Technologies in Pre-Clinical Studies |
| A Look into the Other Key Vaccine Frontrunners |
| CanSino Biologics, Inc. (China) |
| Novavax, Inc. (US) |
| Sanofi/GlaxoSmithKline (France/UK) |
| Merck & Co. (US) |
| MARKET CHALLENGES |
| Global Vaccine Shortage Threatens to Slow Immunization Pace |
| Covid-19 Vaccine Reported Side Effects |
| Women |
| Youngsters |
| People with History of Covid-19 Infection |
| Overcoming/ Avoiding Side Effects |
| New Virus Strains |
| Vaccine Roll Out |
| Vaccine Efficacy and Resistance |
| Supply Challenges |
| Logistics Challenges |
| Distribution Challenges |
| Resistance to Vaccination |
| MARKET DYNAMICS |
| COVID-19 Vaccine Approvals Shifts All Eyes toward Pre-Order and Distribution Statistics |
| VACCINES FOR KIDS |
| Kids: A Key to COVID-19 Mitigation Efforts |
| Some Unanswered Questions |
| Pediatric Research Demands High Safety Bar |
| Uncertainty over Long-Term Adverse Events |
| PMIS Risk among Infected Children Urges Critical Need for COVID-19 Vaccine |
| Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021) |
| Pfizer-BioNTech Initiates Covid Vaccine Trial for Children below 12 Years (March 2021) |
| Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns |
| MRNA: A NEW APPROACH TO MEDICINE |
| mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies |
| RNA Technology: Benefits & Potential for Future Outbreaks |
| Key Challenges |
| mRNA Vaccines Could Vanquish COVID-19 and Cancer |
| Efforts to Target New Application Areas |
| Nanotechnology-based Approach Ensures Higher Loading of Active Ingredient of COVID-19 Vaccine |
| Brazil - A Hotbed for COVID-19 Vaccine Trials |
| Other Important Clinical Trial Locations |
| Key Challenges |
| 3. GLOBAL MARKET SIZE ANALYSIS |
| EXHIBIT 7: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in Millions for Years 2020 through 2025 |
| EXHIBIT 8: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Million Doses for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025 |
| EXHIBIT 9: World Current & Future Analysis for COVID-19 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets - Independent Analysis of Annual Doses in US$ Million for Years 2020 through 2025 |
| EXHIBIT 10: World 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East, and Africa Markets for Years 2021 & 2025 |
| Influencer Market Insights |
| World Market Trajectories |
| COVID-19 VACCINE DEVELOPMENT- A GLOBAL MARKET OVERVIEW |
| COVID-19 Vaccine Launches to Kick Start Economic Recovery |
| Global Reported COVID-19 Cases Surpass 100 Million |
| An Overview of COVID-19 Vaccines Rollout in 2021 |
| COVID-19 Vaccine Approval Details |
| COVID-19 Vaccine Funding Details |
| Pfizer and BioNTech’s Covid-19 Vaccine Receives World’s First Authorization |
| UK Clinches the First Position in the World to Approve Pfizer’s Vaccine |
| Pfizer/BioNTech’s Vaccine Gets US FDA Emergency Use Authorization |
| EU Approves Pfizer’s Vaccine |
| Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production |
| Moderna Bags Coveted Approval from US FDA for COVID-19 Vaccine |
| Moderna Kick-Starts Inoculation in the US |
| First Mover Challenge: Cold Chain Paucity gives Cold Feet to Vaccine Outreach |
| Slow Pace of Covid-19 Vaccines Adoption |
| AstraZeneca’s Vaccine Launch to Bring Cheer this New Year |
| Pfizer/BioNTech vs. Moderna vs. AstraZeneca Vaccine |
| A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine |
| EXHIBIT 3: Production Capacity by Company for Frontrunners in Millions of Doses for 2021 |
| J&J to Approach US FDA for Approval in Early February, 2021 |
| J&J to Seek EU Approval for Potential Vaccine Rollout in April, 2021 |
| Russia’s Sputnik V Receives Approval for People Aged Over 60 in Russia |
| Russia Commences Mass Vaccination in Mid-December |
| Chinese Vaccine Development Scenario |
| China Awards Conditional Approval to First Covid-19 Vaccine from Sinopharm |
| Brazilian Authorities Approve Sinovac’s CoronaVac |
| AstraZeneca’s Covishield and Bharat Biotech’s Covaxin Receive Emergency Use Approval in India |
| BioNTech to Scale Up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU |
| Widespread Rollout of Vaccines to Cut Losses |
| Rampant Preordering by Rich Countries Raises Concerns of Unequal Vaccine Distribution |
| NEW CONTAGIOUS COVID-19 VARIANT ARRIVES |
| COVID-19 Variants Worldwide |
| Scientists Focusing on Newer Strains |
| Mutations Capable of Increasing Transmissibility of Coronavirus among Humans |
| Emerging Variants of Coronavirus in UK and South Africa to be Deadlier than the Early Virus, the US Takes Measures to Curb Spread |
| Work on Booster Vaccine Jab for Fight against the New South African Variant Begins at Moderna, albeit with Caution |
| 4. MARKET DYNAMICS |
| COVID-19 Vaccine Approvals Come with Formidable Distribution Challenges |
| Maintaining Storage Temperature |
| Airfreight Capabilities |
| Focus on Cold Chain Infrastructure for Temperature-Sensitive Covid-19 Vaccines |
| United States Harps on Operation Warp Speed |
| EXHIBIT 11: US GOVERNMENT DEALS WITH VACCINE DEVELOPERS |
| Europe’s Horizon 2020 |
| UK’s Independent Vaccine Deals |
| China – Citizens First |
| COVID-19 Vaccine Frontrunners Sign Vaccine Safety Pledge |
| FDA Plans to Issue Stricter Guidelines for Granting Emergency Covid-19 Vaccine Approvals |
| US States to Prepare for Covid-19 Vaccine Distribution |
| New UN Pledges Poised to Expand Access to Lifesaving Covid-19 Vaccines |
| VACCINE MANUFACTURING AND PROCUREMENT – A GLOBAL INSIGHT |
| EXHIBIT 40: Funding Deals for COVID-19 Vaccine R&D |
| Developed Economies Lead Global Race to Secure COVID-19 Vaccine Supply |
| Licensing and Partnership Deals Worldwide to Propel Vaccine Production |
| EXHIBIT 41: COVID-19 Deals Worldwide - January 2020 to January 2021 |
| Reining in Pandemic Necessitates Fair Access to Resources Globally |
| Vaccine Alliances Ensure Supplies for All |
| ANTI-VACCINE MOVEMENT POSES SIGNIFICANT THREAT |
| Role of COVID-19 Disinformation Campaigns in Growing Vaccine Hesitancy |
| Preventing Anti-Vaxxer Movement from Going Mainstream |
| COVID-19 VACCINES LOGISTICS MANAGEMENT |
| Vaccine Delivery and Success - The Big Task Ahead |
| The Development and Delivery Challenge |
| Planning Amid Uncertainty |
| The Need for a New Approach |
| Building Cold-chain Storage Infrastructure |
| Hopes Pegged to Universal Vaccines with Enhanced Temperature Stability |
| Asians Add Vantage |
| Handling the Skeptical Consumer |
| Efficient Task Force for Greater Success Rates |
| The Importance of Site Selection |
| Workforce Training |
| Consumer Education |
| Government’s Role in Vaccine Distribution |
| Building Cold Chains Crucial for Vaccine Supplies in Africa, Asia and South America |
| Bracing up Networks to Combat Crisis |
| Air Freighters up the Game |
| FIRST RECIPIENTS OF COVID-19 VACCINES |
| EXHIBIT 42: Total Number of Frontline Healthcare Professionals in the US: 2019 |
| EXHIBIT 43: Occupation with the Highest COVID-19 Risks in the US |
| EXHIBIT 45: Food Service Employment by Occupation in the US: 2019 |
| EXHIBIT 46: Total Number of Law Enforcement Officers in the US: 2004 to 2020 |
| INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES |
| The Most Extensive Vaccine Program in the History of Mankind Is Upon US & Many Countries Are Still Unprepared for a Challenge of This Magnitude |
| The Most Extensive Vaccine Program in the History of Mankind Is Upon US & Many Countries Are Still Unprepared for a Challenge of This Magnitude |
| Fair Distribution of COVID-19 Vaccine |
| Vaccine Nationalism to Hamper Equitable Distribution of Vaccines |
| COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine |
| COVAX Inks Additional Deals and Announces Plans for Global Rollout of Covid-19 Vaccines in Early 2021 |
| African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines (September, 2020) |
| COVAX Advance Market Commitment (AMC) |
| World Economic Forum to Push COVID-19 Vaccine Production Capability |
| Pushing Manufacturing Capacity to Fulfil Global Demand |
| Technology Transfer and Other Payments |
| KEY VACCINE TECHNOLOGY PLATFORMS |
| Inactivated Vaccines |
| Inactivated Vaccine Candidate in Preclinical Development: As on January 15, 2021 |
| Protein-Subunit Vaccines |
| Protein-Subunit Vaccine Candidate in Clinical Development: As on January 15, 2021 |
| Non-Replicating Viral-Vector |
| Non-Replicating Viral Vector Vaccine in Preclinical Development: As on January 15, 2021 |
| Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on January 15, 2021 |
| Nucleic Acid Vaccines |
| RNA Vaccine Candidate in Preclinical Studies: As on January 15, 2021 |
| DNA Vaccine Candidate in Preclinical Studies: As on January 15, 2021 |
| Replicating Bacteria Vector |
| Live Attenuated Vaccines (LAVs) |
| Live Attenuated Virus Candidate in Preclinical Studies: As on January 15, 2021 |
| Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on January 15, 2021 |
| Virus-like Particle Vaccines |
| Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on January 5th, 2021 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| CANADA |
| EXHIBIT 21: Canada Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025 |
| Canada Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| JAPAN |
| EXHIBIT 23: Japanese Current & Future Analysis for COVID-19 Vaccines Market: Annual Sales in US$ Million for the Years 2020 through 2025 |
| Japan Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| CHINA |
| China Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| EUROPE |
| Europe Current & Future Analysis for COVID-19 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in Million Doses for Years 2020 through 2025 and % CAGR |
| Europe 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Volume Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020 & 2025 |
| FRANCE |
| France Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| GERMANY |
| Germany Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| ITALY |
| Italy Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| UNITED KINGDOM |
| UK Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| SPAIN |
| Spain Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| RUSSIA |
| Russia Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| ASIA-PACIFIC |
| Asia-Pacific Recent Past, Current and Future Analysis |
| Asia-Pacific Market Analysis: Percentage Share |
| Asia-Pacific Recent Past, Current and Future Analysis |
| Asia-Pacific by Region (In US$ Million) |
| Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in Million Doses for Years 2020 through 2025 and % CAGR |
| Asia-Pacific 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Volume Sales for India and Rest of Asia-Pacific Markets for Years 2020 & 2025 |
| INDIA |
| India Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| LATIN AMERICA |
| Latin America in Million Doses |
| Latin America Percentage Share |
| Latin America Dollar Sales |
| Latin America Percentage Dollar Sales |
| Latin America Current & Future Analysis for COVID-19 Vaccines by Geographic Region - Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in Million Doses for Years 2020 through 2025 and % CAGR |
| Latin America 5-Year Perspective for COVID-19 Vaccines by Geographic Region - Percentage Breakdown of Volume Sales for Brazil, Mexico and Rest of Latin America Markets for Years 2020 & 2025 |
| BRAZIL |
| Brazil Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| MEXICO |
| Mexico Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| REST OF LATIN AMERICA |
| Rest of Latin America Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| MIDDLE EAST |
| Middle East Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| AFRICA |
| Africa Current & Future Analysis for COVID-19 Vaccines by Segment - COVID-19 Vaccines - Independent Analysis of Annual Sales in Million Doses for the Years 2020 through 2025 and % CAGR |
| IV. COMPETITION |
| Total Companies Profiled: 335 |
Focus On COVID-19 Vaccines, One of the Largest Segments in the COVID-19 Vaccines Market.
Will this Market be a Huge Opportunity by 2025?
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com